{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["78"],"submitter":["Koscielniak E"],"pubmed_abstract":["Background
Rhabdomyosarcoma and other soft tissue sarcomas (STS) with high-risk features are still associated with an unsatisfactory outcome. We evaluated the efficacy of oral maintenance therapy added at the end of standard therapy in patients with high-risk rhabdomyosarcoma and STS.Methods
CWS-2007-HR was a multicentre, open-label, randomised controlled, phase 3 trial done at 87 centers in 5 countries. Eligible patients were those aged 6 months to 21 years with non-metastatic incompletely resected embryonal rhabdomyosarcoma occurring in unfavourable sites with unfavourable age (≥10 years) and/or tumour size (>5 cm); all non-metastatic alveolar rhabdomyosarcoma and those with any non-metastatic rhabdomyosarcoma with nodal involvement. A further group was also eligible: pat"],"journal":["EClinicalMedicine"],"pagination":["102957"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11648192"],"repository":["biostudies-literature"],"pubmed_title":["Maintenance therapy with trofosfamide, idarubicin and etoposide in patients with rhabdomyosarcoma and other high-risk soft tissue sarcomas (CWS-2007-HR): a multicentre, open-label, randomised controlled phase 3 trial."],"pmcid":["PMC11648192"],"pubmed_authors":["Muller HL","Koscielniak E","Scheer M","Blank B","Bielack S","Klingebiel T","Behnisch W","Schmid I","Boos J","Blattmann C","Zimmermann M","Teichert von Luttichau I","Hallmen E","Frohlich B","Niggli F","von Kalle T","Ladenstein R","Handgretinger R","Sparber-Sauer M","Ljungman G","Vokuhl C","Kazanowska B"],"additional_accession":[]},"is_claimable":false,"name":"Maintenance therapy with trofosfamide, idarubicin and etoposide in patients with rhabdomyosarcoma and other high-risk soft tissue sarcomas (CWS-2007-HR): a multicentre, open-label, randomised controlled phase 3 trial.","description":"Background
Rhabdomyosarcoma and other soft tissue sarcomas (STS) with high-risk features are still associated with an unsatisfactory outcome. We evaluated the efficacy of oral maintenance therapy added at the end of standard therapy in patients with high-risk rhabdomyosarcoma and STS.Methods
CWS-2007-HR was a multicentre, open-label, randomised controlled, phase 3 trial done at 87 centers in 5 countries. Eligible patients were those aged 6 months to 21 years with non-metastatic incompletely resected embryonal rhabdomyosarcoma occurring in unfavourable sites with unfavourable age (≥10 years) and/or tumour size (>5 cm); all non-metastatic alveolar rhabdomyosarcoma and those with any non-metastatic rhabdomyosarcoma with nodal involvement. A further group was also eligible: pat","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2026-06-02T11:20:18.598Z","creation":"2025-04-04T01:54:59.326Z"},"accession":"S-EPMC11648192","cross_references":{"pubmed":["39687431"],"doi":["10.1016/j.eclinm.2024.102957"]}}